Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open Label Continuation Protocol of a Fixed Dose Combination of Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea

NCT06566820 is registered in ClinicalTrials.gov with Apnimed as lead sponsor.

NCT NCT06566820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06566820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open Label Continuation Protocol of a Fixed Dose Combination of Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea
Lead sponsor
Apnimed
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
July 3, 2024
Completion date
June 30, 2026
Enrollment
1,280 (estimated)
Sites
99

Conditions

As the registry lists them; a condition with its own page is linked.

osa